STOCK TITAN

Rapid Micro Biosystems Inc - RPID STOCK NEWS

Welcome to our dedicated news page for Rapid Micro Biosystems (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rapid Micro Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rapid Micro Biosystems's position in the market.

Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) will announce its first quarter 2024 financial results on May 3, 2024. The company specializes in life sciences technology, providing automation solutions for healthcare product manufacturing. The management team will host a webcast conference call at 8:30 a.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
-
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) will present its innovative Growth Direct® Rapid Sterility Application at the 2024 PDA Annual Meeting. The new application offers fully automated, non-destructive sterility testing with quicker results, significantly reducing incubation time compared to traditional methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
-
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) will participate in the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. The President, CEO, and CFO will engage in a Q&A session, providing insights into the company's mission-critical automation solutions for healthcare product manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
conferences
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) granted stock options and restricted stock units to a new employee under its 2023 Inducement Plan. The options have an exercise price of $0.99 per share, with vesting schedules outlined for both the options and RSUs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) reports strong financial results for Q4 2023 with total revenue of $6.3 million, a 45% growth from Q4 2022. The company generated $22.5 million in revenue for 2023, marking a 31% growth from 2022. They delivered $13.5 million in recurring revenue for 2023 and provided a revenue guidance of at least $27.0 million for 2024, aiming for a 20% growth compared to 2023. The company achieved significant milestones in system placements and partnerships, focusing on innovation and efficiency in the life sciences technology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
-
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) announced its participation in upcoming investor conferences, including TD Cowen 44th Annual Healthcare Conference and KeyBanc Life Sciences & MedTech Investor Forum. The Company will engage in question-and-answer sessions with host analysts, providing live webcasts accessible on their investor relations website for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) will release its Q4 and full-year 2023 financial results on March 1, 2024. The company offers automation solutions for healthcare product manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) expects to launch the Growth Direct Rapid Sterility application by mid-year 2024. The novel, proprietary test kit developed for use with the Company’s fully automated system delivers time to organism detection in as little as 12 hours and final time-to-result in as little as one to three days. This innovation represents a significant improvement over traditional test methods, offering compelling differentiation in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) expects total revenue of $22.4-22.6 million for 2023, representing over 30% growth from the prior year. In the fourth quarter, revenue is expected to be $6.2-6.4 million, a 45% increase from the prior year. The company finished 2023 with $95 million in cash and investments. They also placed six new Growth Direct systems and completed nine validations. Rapid Micro Biosystems will present at the 42nd annual J.P. Morgan Healthcare Conference on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
Rhea-AI Summary
Rapid Micro Biosystems, Inc. (RPID) and Samsung Biologics (207940.KS) have partnered to innovate quality control processes for biomanufacturing. Samsung Biologics has selected Rapid Micro Biosystems' Growth Direct® platform to automate microbial quality control processes, aiming to deliver increased efficiency, data integrity, and scalable quality control operations. This partnership reflects Samsung Biologics' commitment to automation and quality management in biopharmaceutical manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.33%
Tags
none
Rapid Micro Biosystems Inc

Nasdaq:RPID

RPID Rankings

RPID Stock Data

40.61M
9.13M
12.26%
64.97%
0.14%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States
Lowell

About RPID

rapid micro biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products. the company's growth direct(tm) system detects contamination earlier, delivering compelling economic benefits to manufacturers while improving their quality process. the growth direct(tm) system is the first and only automated system that accelerates testing while fitting with current regulatory practices and addressing all key applications.